JP2018537093A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537093A5
JP2018537093A5 JP2018526182A JP2018526182A JP2018537093A5 JP 2018537093 A5 JP2018537093 A5 JP 2018537093A5 JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018537093 A5 JP2018537093 A5 JP 2018537093A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acids
domain
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526182A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537093A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/063034 external-priority patent/WO2017087936A1/en
Publication of JP2018537093A publication Critical patent/JP2018537093A/ja
Publication of JP2018537093A5 publication Critical patent/JP2018537093A5/ja
Priority to JP2021208914A priority Critical patent/JP2022046619A/ja
Priority to JP2024014533A priority patent/JP2024032952A/ja
Pending legal-status Critical Current

Links

JP2018526182A 2015-11-20 2016-11-21 異所性石灰化障害を治療するための組成物およびそれを使用する方法 Pending JP2018537093A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021208914A JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257883P 2015-11-20 2015-11-20
US62/257,883 2015-11-20
PCT/US2016/063034 WO2017087936A1 (en) 2015-11-20 2016-11-21 Compositions for treating ectopic calcification disorders, and methods using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021208914A Division JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Publications (2)

Publication Number Publication Date
JP2018537093A JP2018537093A (ja) 2018-12-20
JP2018537093A5 true JP2018537093A5 (https=) 2020-01-09

Family

ID=58719303

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018526182A Pending JP2018537093A (ja) 2015-11-20 2016-11-21 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2021208914A Pending JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A Pending JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021208914A Pending JP2022046619A (ja) 2015-11-20 2021-12-23 異所性石灰化障害を治療するための組成物およびそれを使用する方法
JP2024014533A Pending JP2024032952A (ja) 2015-11-20 2024-02-02 異所性石灰化障害を治療するための組成物およびそれを使用する方法

Country Status (6)

Country Link
US (4) US20180371434A1 (https=)
EP (2) EP3377105A4 (https=)
JP (3) JP2018537093A (https=)
AU (2) AU2016355715A1 (https=)
CA (1) CA3005142A1 (https=)
WO (1) WO2017087936A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
EP3471747A1 (en) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Methods of treating myointimal proliferation
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
CN120383683A (zh) 2018-08-31 2025-07-29 耶鲁大学 Enpp1多肽及其使用方法
CA3184349A1 (en) * 2020-07-02 2022-01-06 Damon BANKS Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation
CA3195071A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
WO2008105911A2 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
US20080273206A1 (en) * 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
EP3377105A4 (en) * 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH

Similar Documents

Publication Publication Date Title
JP2018537093A5 (https=)
JP2024010052A (ja) 組織石灰化の治療方法
JP6722175B2 (ja) 代謝障害を処置するための組成物及びその使用方法
JP5653909B2 (ja) 抗Siglec−15抗体
JP6059205B2 (ja) CDR改変抗Siglec−15抗体
CA2931309C (en) Compositions and methods for treating pulmonary hypertension
US10646544B2 (en) Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain
JP2018516566A5 (https=)
JP2013127002A5 (https=)
JP2010518079A5 (https=)
CN112741804A (zh) 含有抗pd-l1抗体的稳定制剂
JP2024532831A (ja) アクチビン受容体ii型シグナル伝達阻害剤を使用する方法
CN120623353A (zh) 多特异性wnt替代分子和其用途
JP2011520793A5 (https=)
JP2023027301A (ja) キメラ凝固因子を使用して血友病性関節症を処置する方法
TW201920242A (zh) Glp-2融合多肽及用於治療及預防胃腸病症之用途
JPWO2013147212A1 (ja) 新規抗Siglec−15抗体
KR20160022800A (ko) 당화 vegf 디코이 수용체 융합 단백질
JP2008521426A5 (https=)
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
JP2025116068A (ja) 腎臓活性融合タンパク質及びそれを使用する治療方法
JP2026504047A (ja) 脂質結合タンパク質分子療法
JP2021535078A (ja) 骨の疾患の治療に用いるためのトランスフェリン受容体2のアンタゴニスト及びアゴニスト
US20250352618A1 (en) Methods of treating bronchopulmonary dysplasia
EP4582457A1 (en) Artificial protein and pharmaceutical composition